Pharmacogenomics and Diabetes: Current Progress and Prospects

Prospects of Pharmacogenomics

  • Anam Bilal Institute of Dental Sciences, Sehora 181132, Jammu University, Jammu and Kashmir, India
  • Madiha Mohaimin Institute of Dental Sciences, Sehora 181132, Jammu University, Jammu and Kashmir, India
  • Asma Khurshid DOW Research Institute of Biotechnology and Biomedical Sciences, DOW University of Health Sciences, Ojha Campus, Karachi, Pakistan
Keywords: drug targeting, SNPs, drug development, diabetics, genome, nucleotide polymorphisms

Abstract

Pharmacogenomics describe the influence of an individual's genes on the drug response. With the wide variety of genetic diversity in individuals the response to drugs is also varied. The genetic makeup of a person influences the drug metabolism as well as its efficacy and the appearance    of adverse drug reaction. By studying this relationship between the genes and the drugs can formulate  an individualized treatment which is specific to a person in terms of dosage and efficacy. This would lead to an overall improvement in drug therapy by improving the safety, efficacy profile and reduce the cost and time of treatment and occurrence of adverse side effects. Pharmacogenomics is important   in the development of new drugs. High rate of response variability exist among diabetic patients as   a consequence of genetic diversity of the genes involves in drug response and transport. This review will summarize the targeted strategies towards the genetic variation studies based on drug response and the drug response towards candidate gene involved in diabetes. With the use of pharmacogenomics tools, clinical and genetic data from the patients, it is possible to formulate treatment plans that can reap remarkably favourable results.

 

Published
2025-03-10
Issue
Vol 68 No 1 (2025): Pakistan Journal of Scientific and Industrial Research Series A: Physical Sciences
Section
Articles